Creative Biolabs has unveiled an advanced research platform focused on Bacteroides, a bacterial genus with significant potential in probiotic development and therapeutic interventions. The company's new workflow offers comprehensive services from strain isolation to functional assessment, targeting complex health challenges including metabolic disorders, inflammatory bowel diseases, and potential neurological applications.
The platform's sophisticated approach includes advanced anaerobic cultivation techniques, precise genetic identification using 16S rRNA sequencing and whole-genome analysis, and multi-dimensional functional evaluations. Researchers can now access detailed assessments of bacterial strains, including short-chain fatty acid production, polysaccharide degradation, intestinal cell adhesion, and immune modulation potential.
Biosafety remains a critical focus, with the platform implementing rigorous screening processes to identify potential virulence factors and ensure strain safety. Comprehensive checks include examining hemolytic activity, toxin production, and cytotoxicity to validate the suitability of potential probiotic candidates.
Several key Bacteroides species, including B. fragilis, B. ovatus, and B. thetaiotaomicron, have already been integrated into the platform. These strains offer promising opportunities for functional validation and can be utilized in co-culture and animal model studies.
The development represents a significant step in microbiome research, providing researchers with sophisticated tools to explore the intricate relationships between bacterial strains and human health. By offering both standardized and customized services, Creative Biolabs aims to accelerate translational microbiome therapeutics and support global research partnerships.
